

Entitlement Offer – Closing Date Reminder

Melbourne, Australia; 11 January 2021: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, wishes to remind its shareholders that the Entitlement Offer which was announced on 11 December 2020 closes at 5:00pm (AEDT) on Wednesday, 13 January 2021.

Cynata is pleased to provide its shareholders with the opportunity to participate in the capital raising at the same issue price as the institutional placement which has already raised ~A\$15m. The total capital will enable a significant increase in Cynata’s clinical development pipeline, opening multiple promising new opportunities for the Company’s unique Cymerus™ technology. With a growing interest in induced pluripotent stem cell (iPSC)-driven manufacturing strategies for cell therapy products Cynata remains the global leader with the most advanced product portfolio and strong clinical trial data.

Eligible shareholders who take up their entitlement in full can also apply for additional shares in excess of their entitlement under an oversubscription facility.

The entitlement offer booklet and personalised entitlement and acceptances forms were dispatched to eligible shareholders on 21 December 2020. Eligible shareholders can also access their personalised entitlement and acceptance form by logging onto <https://investor.automic.com.au>.

If you have any questions about the Entitlement Offer, please call the Share Registry on 1300 288 664 or + 612 9698 5414 (outside Australia) at any time from 8:30am to 5:00pm (AEDT) on Monday to Friday during the Entitlement Offer period.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com
Claire LaCagnina, U.S. Media Contact, +1 315.765.1462, clacagnina@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata has active clinical trials, using its Cymerus™ MSCs for a Phase 3 trial in osteoarthritis and a Phase 2 trial in severe complications arising from COVID-19. Cynata plans to advance into trials for GvHD (through licensee Fujifilm) and critical limb ischemia. Cynata is planning for additional clinical programs in further indications (including idiopathic pulmonary fibrosis, renal transplantation, and diabetic foot ulcers), following encouraging pre-clinical data. In addition, Cynata has demonstrated utility of its Cymerus™ MSC technology in preclinical models of asthma, diabetic wounds, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.